To assess the effect of currently available therapeutic inhibitors targeting GBP1, we used NSC756093 that interrupts the interaction between GBP1 and proto-oncogene serine/threonine-protein kinase (PIM1), the inhibition of which could potentially revert paclitaxel resistance in cancer cells (Andreoli et al., 2014). The gene discussed is PIM1; the disease is cancer.